Journal Article
. 2007 Feb; 25(6):656-61.
doi: 10.1200/JCO.2006.07.0847.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)

Hannah M Linden 1 Charles M Haskell  Stephanie J Green  C Kent Osborne  George W Sledge  Charles L Shapiro  James N Ingle  Danika Lew  Laura F Hutchins  Robert B Livingston  Silvana Martino  
Affiliations
  • PMID: 17308269
  •     15 citations

Abstract

Purpose: We conducted a phase III randomized study of two adjuvant treatment schedules of doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration of sequential single agents (A --> C) results in superior disease-free survival (DFS) and overall survival (OS) versus the same total dose given in combination (AC).

Patients And Methods: High-risk node-negative or low-risk node-positive breast cancer patients received AC given: (arm I) concurrently (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles; or (arm II) in sequence (A C) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles. Total dose and duration were identical, but the intensity of each drug was increased on A C. Both arms included granulocyte colony-stimulating factor support and prophylactic antibiotics. All but premenopausal women with receptor negative tumors received tamoxifen after chemotherapy.

Results: Between 1994 and 1997, 3,176 patients were randomly assigned. Arms were well balanced; 48% of eligible patients were node-negative and 48% were estrogen receptor-positive. No significant differences in OS or DFS were observed; 5-year estimates of OS (95% CI) were 88% (87% to 90%) on AC and 89% (87% to 91%) on A --> C. Grade 4 hematologic toxicity was greater on A --> C, but nonhematological grade 4 was similar.

Conclusion: The overall result does not support superiority of dose-intense sequenced single agents. The greater toxicity of higher doses of single agents does not support their sequential use.

p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
Peggy L Porter, William E Barlow, +11 authors, Daniel F Hayes.
J Natl Cancer Inst, 2006 Dec 07; 98(23). PMID: 17148774    Free PMC article.
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Raymond Tubbs, William E Barlow, +11 authors, Daniel F Hayes.
J Clin Oncol, 2009 Jul 22; 27(24). PMID: 19620488    Free PMC article.
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
Malini Harigopal, William E Barlow, +10 authors, Daniel F Hayes.
Am J Pathol, 2010 Feb 13; 176(4). PMID: 20150438    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.
Orit Freedman, Eitan Amir, Camilla Zimmermann, Mark Clemons.
Support Care Cancer, 2011 Jan 05; 19(3). PMID: 21203780
Systematic Review.
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
Mary W Redman, Bryan H Goldman, +2 authors, Laurence H Baker.
Clin Cancer Res, 2013 May 15; 19(10). PMID: 23669424    Free PMC article.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
Comparison of survival outcomes among cancer patients treated in and out of clinical trials.
Joseph M Unger, William E Barlow, +4 authors, Dawn L Hershman.
J Natl Cancer Inst, 2014 Mar 15; 106(3). PMID: 24627276    Free PMC article.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Review.
Impact of chemotherapy on perceptions related to food intake in women with breast cancer: A prospective study.
Eduarda da Costa Marinho, Isis Danyelle Dias Custódio, +3 authors, Yara Cristina de Paiva Maia.
PLoS One, 2017 Dec 01; 12(11). PMID: 29190717    Free PMC article.
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
P Sharma, W E Barlow, +10 authors, D F Hayes.
Ann Oncol, 2018 Jan 03; 29(3). PMID: 29293876    Free PMC article.
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Priyanka Sharma, William E Barlow, +19 authors, Daniel F Hayes.
J Clin Oncol, 2019 Oct 29; 37(36). PMID: 31657982    Free PMC article.
Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
Elvira C van Dalen, Helena J H van der Pal, Leontien C M Kremer.
Cochrane Database Syst Rev, 2016 Mar 05; 3. PMID: 26938118    Free PMC article.
Systematic Review.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Review.
Re: p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
Paul N Span, Pieter H de Mulder, Fred C G J Sweep.
J Natl Cancer Inst, 2007 May 02; 99(9). PMID: 17470742    Free PMC article.